The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis — possible applications of anti-RANKL antibody to the treatment of cancer patients-Reference-Cited by-同舟云学术

The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis — possible applications of anti-RANKL antibody to the treatment of cancer patients

Published:2019 Issue:1 Volume:153 Page:11-15
ISSN:0015-5691
Container-title:Folia Pharmacologica Japonica
language:en
Short-container-title:Folia Pharmacol. Jpn.

Author:

Yasuda Hisataka¹

Affiliation:

1. Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd.

Publisher

Japanese Pharmacological Society

Subject

Pharmacology

Link

https://www.jstage.jst.go.jp/article/fpj/153/1/153_11/_pdf

Reference37 articles.

1. 1) Yasuda H, et al. Proc Natl Acad Sci U S A. 1998;95:3597-3602.

2. 2) Nakagawa N, et al. Biochem Biophys Res Commun. 1998;253:395-400.

3. 3) Tsuda E, et al. Biochem Biophys Res Commun. 1997;234:137-142.

4. 4) Simonet WS, et al. Cell. 1997;89:309-319.

5. 5) Yasuda H, et al. Endocrinology. 1998;139:1329-1337.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facile fabrication of phosphazene-quercetin-alendronate composites as pH-responsive bone-targeted nanomedicine for osteoporosis treatment;Materials & Design;2024-05

2. Research Progress on the Application of Deshumazumab in Osteoporosis;Advances in Clinical Medicine;2023

3. Differentially expressed genes and miRNAs in female osteoporosis patients;Medicine;2022-07-15

4. Emerging roles for myeloid immune cells in bone metastasis;Cancer and Metastasis Reviews;2021-04-14

5. Tranexamic Acid Protects Ovary and Testis Functions and Ameliorates Osteoporosis in Mice;Pharmacology;2020